We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The panel also underlined that pharma PSUs like Hindustan Antibiotics, IDPL, etc. are facing very stiff competition from foreign companies, particularly, the Chinese ones.